Dermatology Times Newsletter

To view this email as a web page, click here.

You’re reading Innovations, a column from Steve Xu, M.D., FAAD, co-founder of Advancing Innovation in Dermatology Accelerator. Do you have a topic you’d like Dr. Xu to discuss? Let us know.

What is technology transfer?

Dr. Xu begins the first part of a two-part mini-series discussing what innovators should know about intellectual property. This installment focuses on the different scenarios innovators may run into when dealing with the transfer of technological property, called technology transfer.

How do you use a patent?

In this follow up to last month’s Innovations column on intellectual property and technology transfer, Raymond A. Miller, J.D., and Steve Xu, M.D., FAAD discuss how to utilize patents to maximize value for your venture.

Can you identify the appropriate treatment for newly diagnosed patients?

In a treatment naive patient with severe psoriatic arthritis, what treatment is suggestive based on the latest American College of Rheumatology treatment guidelines? Test yourself.

Subscribe Today to the Aesthetics Innovators Podcast!

The Aesthetics Innovators Podcast provides an inside look into the most exciting approaches, strategies and companies in the industry. Join the conversation by subscribing today at

https://attendais.com/podcast/

From our Latest Issue

My AI will see you now

Advances in squamous cell carcinoma management

Immunotherapies for Staphylococcus aureus

JOB OPPORTUNITIES

CA - Integrated Dermatology

CO-Integrated Dermatology

CT - Integrated Dermatology

District of Columbia-Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

MS - Integrated Dermatology

National - Integrated Dermatology

NJ - Integrated Dermatology

NJ - Practice for Sale

NV - Integrated Dermatology

VA - Integrated Dermatology

VT - Integrated Dermatology

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.